Uracil reductase inactivators
Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C 1-4 alkyl, C 2-6 alkenyl, 1-halo-C 2-6 alkenyl and halo-substituted C 2-6 alkynyl.
1. A pharmaceutical composition, comprising (i) an amount effective to enhance 5-fluorouracil activity of a 5-substituted- or 5,6-dihydro-5-substituted-uracil derivative, wherein the substituent at the 5 position is halo substituted C 1-4 alkyl, C 2-6 alkenyl, 1-halo-C 2-6 alkenyl, or C 2-6 alkynyl and a pharmacutically acceptable carrier or excipient.
2. The pharmaceutical composition of claim 1 , wherein the uracil derivative is 5-ethynyluracil.
3. The pharmaceutical composition of claim 1 , wherein the uracil derivative is 5-propynyl uracil.
4. The pharmaceutical composition of claim 1 , wherein said composition is adapted for oral administration.
5. The pharmaceutical composition of claim 4 , wherein said composition is a tablet or capsule.